Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New AI Algorithms Enable Diagnosis of Difficult Cancers

By LabMedica International staff writers
Posted on 07 Dec 2023

A team of European researchers and companies, led by the Valencia Polytechnic University (UPV, Valencia, Spain), through the CVBLab-HUMAN-tech group, has developed novel artificial intelligence (AI) algorithms to aid the diagnosis and treatment of cancerous tumors that are difficult to interpret clinically. More...

This is one of the main results of the CLARIFY project, which is now in its final months of execution.

CLARIFY is an innovative, multinational, multi-sectorial, and multidisciplinary research initiative with a focus on developing a robust automated digital diagnostic environment based on AI and cloud-oriented data algorithms. The goal is to streamline the interpretation and diagnosis of whole-slide-images (WSIs) globally, to optimize the advantages of digital pathology, and to support pathologists in their routine tasks. The project has concentrated on specific and difficult-to-diagnose cancer types to evaluate the effectiveness of the tools and methods it has developed. These include Triple Negative Breast Cancer (TNBC), High-risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC), and Spitzoid Melanocytic Lesions (SML), representing the diverse challenges present in cancer diagnosis.

Furthermore, the CLARIFY project has yielded additional noteworthy results, such as the creation of comprehensive databases for the studied cancers. These databases are poised to be valuable assets for the medical and scientific communities. The project has also made progress in the secure handling of data in cloud environments, addressing the unique requirements of the healthcare sector. This includes several practical applications within the project's framework, enhancing data security and management.

“In all three cases, the diagnosis is complex and challenging, which we are already addressing with this project,” said Valery Naranjo, project leader. “With these algorithms, we are taking another step forward in facilitating the interpretation of histological images and, ultimately, the diagnosis of these types of cancer for medical professionals.”

Related Links:
Valencia Polytechnic University


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.